US81577F2083 - Common Stock
SEELOS THERAPEUTICS INC
NASDAQ:SEEL (5/7/2024, 7:22:12 PM)
After market: 0.3008 +0.01 (+2.28%)0.2941
-0.02 (-6.99%)
Seelos Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 16 full-time employees. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing programs include SLS-004, SLS-006, and SLS-007.
SEELOS THERAPEUTICS INC
300 Park Avenue, 2nd Floor
New York City NEW YORK 10022
P: 16462932100
CEO: Raj Mehra
Employees: 16
Website: https://seelostherapeutics.com/
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...
It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!
SEEL stock results show that Seelos Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Seelos Therapeutics (NASDAQ:SEEL) just reported results for the fourth quarter ...
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for...
The FDA priority review for an MDMA-linked therapy leads to a surge in shares of psychedelic medicine companies such as Mind Medicine (MNMD). Read more here.
Here you can normally see the latest stock twits on SEEL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: